<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1635">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832945</url>
  </required_header>
  <id_info>
    <org_study_id>8953</org_study_id>
    <nct_id>NCT04832945</nct_id>
  </id_info>
  <brief_title>SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study</brief_title>
  <official_title>Multicenter Retrospective Cohort Study of Ivermectin as a SARS-CoV-2 Pre-exposure Prophylactic Method in Healthcare Workers in Dominican Republic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Rescue S.A.S República Dominicana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Rescue S.A.S República Dominicana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study, a multicenter retrospective cohort database study, carried out in&#xD;
      two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta&#xD;
      Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a&#xD;
      weekly orally dose of 0.2 mg/kg, is an effective pre-exposure prophylactic method (PrEP) for&#xD;
      the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in the healthcare&#xD;
      workers. The study began on June 29, 2020 and ended on July 26, 2020 (4 weeks).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Actual">April 10, 2021</completion_date>
  <primary_completion_date type="Actual">September 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants RT-PCR positive for Covid-19</measure>
    <time_frame>4 weeks</time_frame>
    <description>Workers confirmed Covid-19 through Reverse Transcription Polymerase Chain Reaction (RT-PCR) test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of sick participants who condition deteriorated</measure>
    <time_frame>4 weeks</time_frame>
    <description>Workers infected with Covid-19, confirmed with RT-PCR and required hospitalization and/or ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sick participants who died</measure>
    <time_frame>4 weeks</time_frame>
    <description>Workers infected with Covid-19, confirmed with RT-PCR and died.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">713</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ivermectin Group</arm_group_label>
    <description>Healthcare personnel receiving Ivermectin weekly PrEP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Healthcare personnel not receiving Ivermectin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 6 Mg Oral Tablet</intervention_name>
    <description>Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks</description>
    <arm_group_label>Ivermectin Group</arm_group_label>
    <other_name>Ivermectin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Workers who was part of Ivermectin prophylaxis program and signed the informed consent at&#xD;
        CMPC and CMBO in Dominican Republic was analyzed and included in the intervention group.&#xD;
        Those who didn't participate in the prophylaxis program but were on active duty during the&#xD;
        4 weeks of the study were included in the control group.&#xD;
&#xD;
        Workers excluded from Ivermectin prophylaxis program was:&#xD;
&#xD;
          -  Pregnant or suspected pregnant women&#xD;
&#xD;
          -  Women breastfeeding&#xD;
&#xD;
          -  Patients receiving coumarin anticoagulants&#xD;
&#xD;
          -  Those allergic to Ivermectin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active workers from Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC)&#xD;
             during the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Workers with positive Covid-19 RT-PCR prior to the start of the study&#xD;
&#xD;
          -  Those that did not take the first dose of Ivermectin the first week at the start of&#xD;
             the study&#xD;
&#xD;
          -  Those that did not complied with at least 2 out of 4 weekly doses&#xD;
&#xD;
          -  Those that had greater than 14 days difference in days between two intakes Ivermectin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Morgenstern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Rescue</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Natalio Redondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Rescue</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvaro Olavarria, Data Analyst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Rescue</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Medico Bournigal</name>
      <address>
        <city>Puerto Plata</city>
        <zip>57000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Punta Cana</name>
      <address>
        <city>Punta Cana</city>
        <zip>23000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ivermectin</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>PrEP</keyword>
  <keyword>Covid-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

